Clinical Trials
72 trialsUmbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
Ohio State University Comprehensive Cancer Center
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
Incyte Corporation
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Incyte Corporation
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
Incyte Corporation
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
Connect® Myeloid Disease Registry
Celgene
FREEDOM
Celgene
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
Astex Pharmaceuticals, Inc.
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
Astex Pharmaceuticals, Inc.
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Incyte Corporation
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis
AbbVie
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
Asana BioSciences
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
Roswell Park Cancer Institute
Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis
University of Utah
Study of INCB053914 in Subjects With Advanced Malignancies
Incyte Corporation
PAC326
CTI BioPharma
USBTXA127CBT
Tarix Pharmaceuticals
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
CTI BioPharma
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
M.D. Anderson Cancer Center
18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms
Hamad Medical Corporation
Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia
M.D. Anderson Cancer Center
AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis
NYU Langone Health
iCare for Cancer Patients
University of Florida
T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Fred Hutchinson Cancer Center
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
City of Hope Medical Center
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Incyte Corporation
Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis
M.D. Anderson Cancer Center
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Barbara Ann Karmanos Cancer Institute
Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)
M.D. Anderson Cancer Center
Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT
Stanford University
Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer
Vanderbilt-Ingram Cancer Center
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Emory University
POE07-01
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
Masonic Cancer Center, University of Minnesota
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Masonic Cancer Center, University of Minnesota
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
OHSU Knight Cancer Institute
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
Fred Hutchinson Cancer Center
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant
OHSU Knight Cancer Institute
Blood Samples From Patients on a Clinical Trial to CINV During HSCT
OHSU Knight Cancer Institute
Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome
Rutgers, The State University of New Jersey
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer
University of Rochester
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
Alliance for Clinical Trials in Oncology
Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis
Mayo Clinic
Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment
City of Hope Medical Center